ACTG A5188(V 10):TRNSDRML CNTRACPTV SYSTM&ORAL CNTRACPTV IN HIV-1 WOMEN W/L/R

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究将观察服用两种不同类型的节育措施后体内的激素水平，即ORTHO EVRA贴片和ORTHO NOVUM药片。目前尚不清楚同时服用ORTHO EVRA或ORTHO NOVUM和抗艾滋病毒药物是否会改变女性体内的激素量或抗艾滋病毒药物水平。美国食品和药物管理局（FDA）已经批准了ORTHO EVRA和ORTHO NOVUM用于避孕，但它们尚未在服用Kaletra的HIV-1感染妇女中进行测试。ORTHO EVRA贴片和1片ON 1/35片剂将由研究提供。所有参与者将接受1片ON 1/35药丸，然后每周接受ORTHO EVRA贴片，持续3周。包括Kaletra在内的抗艾滋病药物不在研究范围内。参见下面的架构：

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will look at hormone levels in the body after taking two different types of birth control, the ORTHO EVRA patch and the ORTHO NOVUM pill. It is not known if taking ORTHO EVRA or ORTHO NOVUM and anti-HIV medication at the same time will change the amount of hormone or anti-HIV drug levels in a woman's body. The Food and Drug Administration (FDA) has approved ORTHO EVRA and ORTHO NOVUM for contraception, but they have not yet been tested in HIV-1 infected women taking Kaletra. The ORTHO EVRA patch and one ON 1/35 tablet will be supplied by the study. All participants will receive one ON 1/35 pill and then receive the ORTHO EVRA patch weekly for 3 weeks. Anti-HIV drugs, including Kaletra, are not supplied by the study. See Schema below: